Last Updated: August 9, 2026

Patent: 9,815,886


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,815,886
Title:Compositions and methods for the treatment of immunodeficiency
Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
Inventor(s): Grossman; Adam S. (Saddle River, NJ), Mond; James (Silver Spring, MD), Grossman; Jerrold B. (Saddle River, NJ), Goldstein; Dov A. (New York, NY)
Assignee: ADMA BIOLOGICS, INC. (Ramsey, NJ)
Application Number:14/592,727
Patent Claims:see list of patent claims

Details for Patent 9,815,886

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Adma Biologics, Inc. NABI-HB hepatitis b immune globulin (human) Injection 103945 October 23, 2001 ⤷  Start Trial 2035-01-08
Octapharma Pharmazeutika Produktionsges.m.b.h. OCTAGAM immune globulin intravenous (human) Injection 125062 May 21, 2004 ⤷  Start Trial 2035-01-08
Octapharma Pharmazeutika Produktionsges.m.b.h. OCTAGAM immune globulin intravenous (human) Injection 125062 March 26, 2007 ⤷  Start Trial 2035-01-08
Octapharma Pharmazeutika Produktionsges.m.b.h. OCTAGAM immune globulin intravenous (human) Injection 125062 July 11, 2014 ⤷  Start Trial 2035-01-08
Adma Biologics, Inc. BIVIGAM immune globulin intravenous (human) Injection 125389 December 19, 2012 ⤷  Start Trial 2035-01-08
Takeda Pharmaceuticals U.s.a., Inc. ADYNOVATE antihemophilic factor (recombinant), pegylated For Injection 125566 November 13, 2015 ⤷  Start Trial 2035-01-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 9,815,886

Country Patent Number Estimated Expiration
South Africa 201707303 ⤷  Start Trial
World Intellectual Property Organization (WIPO) 2016069693 ⤷  Start Trial
United States of America 10683343 ⤷  Start Trial
United States of America 11339206 ⤷  Start Trial
United States of America 11780906 ⤷  Start Trial
United States of America 12473351 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.